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Abstract
Genome-wide association studies (GWAS) have successfully identified loci associated with quantitative traits, such as blood
lipids. Deep resequencing studies are being utilized to catalogue the allelic spectrum at GWAS loci. The goal of these studies
is to identify causative variants and missing heritability, including heritability due to low frequency and rare alleles with
large phenotypic impact. Whereas rare variant efforts have primarily focused on nonsynonymous coding variants, we
hypothesized that noncoding variants in these loci are also functionally important. Using the HDL-C gene LIPG as an
example, we explored the effect of regulatory variants identified through resequencing of subjects at HDL-C extremes on
gene expression, protein levels, and phenotype. Resequencing a portion of the LIPG promoter and 59 UTR in human
subjects with extreme HDL-C, we identified several rare variants in individuals from both extremes. Luciferase reporter
assays were used to measure the effect of these rare variants on LIPG expression. Variants conferring opposing effects on
gene expression were enriched in opposite extremes of the phenotypic distribution. Minor alleles of a common regulatory
haplotype and noncoding GWAS SNPs were associated with reduced plasma levels of the LIPG gene product endothelial
lipase (EL), consistent with its role in HDL-C catabolism. Additionally, we found that a common nonfunctional coding variant
associated with HDL-C (rs2000813) is in linkage disequilibrium with a 59 UTR variant (rs34474737) that decreases LIPG
promoter activity. We attribute the gene regulatory role of rs34474737 to the observed association of the coding variant
with plasma EL levels and HDL-C. Taken together, the findings show that both rare and common noncoding regulatory
variants are important contributors to the allelic spectrum in complex trait loci.
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Introduction
Numerous studies have associated low levels of high density
lipoprotein cholesterol (HDL-C) with an increased risk of
developing coronary heart disease (CHD) [1,2,3,4,5,6,7]. HDL-
C levels are approximately 50% heritable [8]. Genome-wide
association studies (GWAS) for lipid traits have identified many
genes previously associated with HDL metabolism and numerous
novel loci [9,10,11,12,13,14]. However, the identification of the
causal variants in these loci has proven difficult. Resequencing
studies have not identified common coding variants that explain
the associations. Such results may suggest that causal coding
variants are rarer than anticipated [15] or lie in the gene
regulatory regions. Furthermore, many of the variants identified
by GWAS are embedded in gene deserts. Although a portion of
these associated variants may tag less-common variants with
strong phenotypic effects, some noncoding variants are likely to be
causal themselves [16]. Nevertheless, combining the variation
PLoS Genetics | www.plosgenetics.org 1 December 2011 | Volume 7 | Issue 12 | e1002393explained by all of the common variants identified to date leaves
missing heritability [17] that may be explained, at least in part, by
rare variants.
Several HDL-C candidate genes, including those with known
physiological relevance to HDL-C metabolism, have been
characterized though targeted gene-resequencing approaches
[18]. Through these studies, the exons of HDL-C candidate genes
(ABCAI, APOAI, LCAT) [19] and other mechanistically implicated
genes (ANGPTL4, LIPG) [20,21] have been sequenced in
individuals at the extremes of the HDL-C phenotypic distribution.
Rare coding loss-of-function variants were shown to segregate with
the phenotype in a manner consistent with the known physiolog-
ical role of the gene product in increasing or decreasing HDL-C
levels. Causality of the identified variants was shown through a
combination of in vitro functional studies and computational
methods. Because the occurrence of each rare variant was too low
to test its association in our sequencing cohorts, individual variants
in each phenotypic extreme were grouped together (‘‘collapsed’’),
and the total number of rare variants in the sequenced region was
compared between cohorts. This method of rare variant
association analysis, known as the cohort allelic sums test (CAST)
[22,23], has been instrumental in showing that rare loss-of-
function variants modulate HDL-C levels in humans. However,
few studies to date have utilized this approach to study rare
regulatory variants, which do not always segregate with the
phenotypic extremes of continuous traits as stringently as
deleterious nonsynonymous variants. Additionally, the functional
validation of identified variants in regulatory regions can be
challenging, especially for unknown promoter or regulatory
elements.
In the last decade, several HDL-C candidate genes have been
identified, including many with large regulatory regions implicated
in association studies. These findings, combined with the fact that
HDL-C exists as a continuously distributed trait, make HDL-C
candidate genes well-suited for understanding how rare regulatory
variants influence complex traits. One HDL-C candidate gene
associated in GWAS is LIPG [9,10,11,12,13,24,25], which encodes
endothelial lipase (EL), a conserved plasma phospholipase
expressed from endothelial cells [26,27]. Compared to other
plasma proteins, EL exhibits preferential HDL phospholipolysis
activity in vitro [28]. Somatic overexpression of EL in mice causes a
dose-dependent reduction in plasma HDL-C levels [29], whereas
targeted deletion of LIPG [30] or inhibition of EL using polyclonal
antibodies [31] raises HDL-C levels in vivo.
We recently identified rare loss-of-function coding variants in
subjects with high HDL-C through a resequencing study of
subjects at the extremes of the HDL-C phenotypic distribution
[20]. Here, we expand our initial resequencing effort to include
regulatory variations, thereby further characterizing the allelic
spectrum of LIPG. Our findings show that both rare and common
variations in regulatory regions of LIPG affect LIPG expression,
plasma EL protein concentrations, and HDL-C levels.
Results
Identification and functional assessment of novel rare
LIPG regulatory variants
We sequenced a portion of the promoter and the 59 UTR
(1755-bp immediately upstream of the transcription start site) in
388 unrelated individuals. Of the sequenced individuals, 195
individuals had extremely high HDL-C levels ($95
th percentile;
HHDL Sequencing Cohort) and 193 had low HDL-C levels
(#25
th percentile; LHDL Sequencing Cohort). A summary of the
characteristics of the participants in the sequencing cohorts
appears in Table 1. Through this study, we identified a total of
22 rare and common LIPG regulatory variants in the region
sequenced (Figure 1).
25 individuals from our sequencing cohorts harbored a rare
variant (minor allele frequency [MAF],1%) in the proximal
promoter or 59 UTR of LIPG. Of these 25 individuals, 16 were in
the HHDL and 9 were in the LHDL Sequencing Cohort (Table 2).
The main characteristics of each of these participants are
summarized in Table S1. Of the 17 individual rare LIPG
regulatory mutations we identified, 10 were found only in
individuals with high HDL-C, 5 occurred only in individuals with
low HDL-C, and the remaining 2 occurred in individuals from
both cohorts. We did not find a disproportionate frequency of rare
regulatory variants between the HHDL and LHDL cohorts
(P=0.2142, Table 3).
We also searched for these variants in the 1000 Genomes
Project database (451 participants; [32]) and found that only the 2
variants present in both cohorts, 2303 A.G and 2324 A.G,
occurred in individuals of the YRI ethnicity in this database
(MAF=0.014 for 2303 A.G, MAF=0.024 for 2324 A.G).
Neither of these variants was present in 1000 Genomes Project
participants of other ethnicities, nor were any of the other 15
variants present in any population from this study.
To determine the functional significance of the identified
variants in modulating LIPG promoter activity, variants were
tested with a luciferase reporter assay in HUVECs, which
endogenously express LIPG. A wild-type LIPG promoter construct
corresponding to the sequenced portion of the LIPG promoter was
constructed and tested against the promoter-less pGL3-basic
construct. The WT LIPG promoter construct displayed approx-
imately 31.9 times greater relative luciferase activity than the
pGL3-basic construct (Figure S1).
We tested promoter constructs corresponding to the rare LIPG
variants. Four of the 10 rare variants found only in high HDL-C
individualsdisplayeddecreasedpromoteractivityrelativetotheWT
promoter construct (Figure 2A). In contrast, 4 of the 5 rare variants
found only in low HDL-C individuals displayed increased promoter
activity (Figure 2B). The remaining 6 variants identified in only in
Author Summary
Genetic association studies have identified genomic
regions that affect quantifiable traits such as lipid levels.
When a gene and a trait are found to be associated with
one another, the gene is often further studied to
determine its role in affecting the trait. One approach is
to sequence the gene in individuals at the extremes of the
trait’s distribution with the hope of finding rare mutations
that directly contribute to the trait. Until now studies using
this approach have focused on genetic variation in the
protein coding sequence of these genes and have been
largely successful in identifying functionally important
mutations. However, other studies have found an abun-
dance of noncoding variation in the genome that may also
contribute to the heritability of these traits. Here we seek
to determine the contribution of such noncoding muta-
tions to high density lipoprotein cholesterol (HDL-C) levels
in humans using the HDL-C candidate gene LIPG as an
example. Through a sequencing study in individuals with
high and low HDL-C levels, we demonstrate that both rare
and common noncoding mutations are influential con-
tributors to the allelic spectrum of such traits and should
be further characterized after initial association with the
trait.
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C individuals did not alter promoter activity relative to WT (Figure
S2A and S2B). One of the 2 rare regulatory variants found at both
extremes (2303 A.G) caused increased promoter activity in vitro
(Figure S2C). Six individuals from the HHDL Sequencing Cohort
had a rare regulatory variant decreasing LIPG expression in vitro,
compared to no individuals from the LHDL Sequencing Cohort
(P=0.0301, Fisher’s exact test, Table 3). One individual from the
HHDLSequencing Cohort had a rare regulatory variant increasing
promoter activity, compared with 7 individuals from the LHDL
Sequencing Cohort (P=0.0364, Table 3).
Next, we individually compared the number of individuals with
functional rare regulatory variants identified in either sequencing
cohort. We excluded the 2 regulatory mutations that were
identified in individuals from both cohorts and reassessed the
association of functional rare regulatory variants with the
phenotypic extremes. Similar to the results obtained above, a
significant excess of rare LIPG promoter variants causing
decreased LIPG expression was found in individuals with high
HDL-C (P=0.0301, Table 3), and an excess of rare variants
causing increased promoter activity was found in individuals with
low HDL-C (P=0.0297, Table 3). Notably, when we enriched for
variants only present in either of the cohorts, no variants
decreasing LIPG promoter activity in vitro were identified in
individuals with low HDL-C. Likewise, no variants increasing
promoter activity were present in individuals with high HDL-C.
Table 1. Baseline characteristics of participants in LIPG promoter resequencing.
HHDL Sequencing Cohort (N=195) LHDL Sequencing Cohort (N=193)
Ascertainment Physician referral, HDL$95th PCTL Physician referral, HDL#25th PCTL
Ethnic composition 92.2% Caucasian, 7.8% Black 91.7% Caucasian, 8.3% Black
Mean age (y) 60.4611.9 57.5613.9
Female (%) 58 58
HDL (mg/dL) 109.1617.9 33.966.2
BMI (kg/m
2) 23.262.8 29.365.5
Values are given as mean 6 standard deviation except for ethnic composition and sex; PCTL, percentile.
doi:10.1371/journal.pgen.1002393.t001
Figure 1. Rare and common LIPG regulatory variants studied. Diagram of Chr. 18q21.1 region containing LIPG with variants identified
annotated.
doi:10.1371/journal.pgen.1002393.g001
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regulatory variants associated with HDL-C
In addition to discovering novel, rare LIPG regulatory variants,
our sequencing effort identified 5 common variants (MAF$5%),
all of which were present in both high HDL-C and low HDL-C
subjects (Figure 1 and Table 4). The minor alleles of 3 of the
identified variants (rs9959847, 21495 T.C; rs4245232, 21429
C.A; rs3829632, 21309 A.G) are in complete LD with each
other and constitute a common haplotype. According to the
International HapMap Project dataset [33], this haplotype
includes 3 additional SNPs upstream of the sequenced region
(rs4939583, rs6507929, rs4939875) and 2 intronic SNPs
(rs2000812, rs3819166) (Figure 1, Table S2, Figure S3). We
assessed the association of 2 of the identified common variants,
21309 A.G (rs3829632) and 21358 (T insertion), with HDL-C
and other HDL traits in the Framingham Heart Study Offspring
cohort (FHS; 1089 subjects in this analysis, Table 5). The 21309
A.G variant was used as a tag SNP for the haplotype. Although
the 21358 (T insertion) variant had a borderline association with
decreased HDL3 subfraction, the 21309 A.G variant (and, thus,
the entire haplotype) was strongly associated with decreased HDL-
C by approximately 2 mg/dL (P,0.0002). This latter variant was
also associated with decreases in HDL3, large HDL particles,
apoA-I (the major protein component of all HDL), and HDL size.
Consistent with these findings, a recent GWAS of .100,000
individuals by the Global Lipids Genetics Consortium (GLGC)
found that the minor alleles of several variants of this haplotype
were strongly associated with a reduction in HDL-C (Table S2)
[13]. Neither the 21358 (T insertion) or 21309 A.G variants
were associated with changes in any other lipid or lipoprotein
measures in the FHS (data not shown).
Functional analysis of common LIPG regulatory variants
Reporter constructs corresponding to the common LIPG
regulatory variant rs34474737 (229 T.G) and the 21358 T
insertionvariant,neither ofwhichisknown tobepart ofahaplotype
extending beyond the LIPG promoter, were generated and used to
test their impact on LIPG promoter activity in HUVECs (Figure 3).
The rs34474737 variant caused a marked reduction in luciferase
reporter activity (P,0.01 vs. WT), whereas the 21358 (T insertion)
variant,whichwasnotstronglyassociated withmodulationofHDL-
C in FHS, did not significantly alter LIPG promoter activity.
We hypothesized that the common LIPG regulatory variant
rs34474737, which decreases promoter activity in vitro, would
cause decreased plasma levels of EL in human subjects. If true, this
finding would provide a mechanism through which the identified
variants could increase HDL-C levels in humans. We also assessed
the role of 2 recently associated noncoding variants (rs2156552
and rs4299883) and the common haplotype spanning the LIPG
locus (rs3829632, 21309 A.G) in the regulation of LIPG
expression, by testing the effects of these variants on plasma EL.
The EL concentrations were measured in participants of the
SIRCA study who were genotyped for variants rs34474737
(n=761), rs2156552 (n=570), rs4299883 (n=755), and
rs3829632 (n=760) (Table 6).
Minor alleles of the rs4299883 and rs2156552 variants were
highly associated with decreased HDL-C in the GLGC GWAS
(P,10
244 and P,10
248 respectively) [13]. We tested the
association of these 2 variants with HDL-C and HDL subpheno-
types in the FHS, and found that the minor alleles of these variants
are associated with decreased HDL-C, HDL2, HDL3, and HDL
particle sizes and apoA-I levels (Table 5). Consistent with these
findings, the minor alleles of these variants were also associated
with increased plasma EL (P,0.002 and P,0.004, respectively)
(Table 6). The minor allele of the 21309 A.G variant was
moderately associated with increased plasma EL (P,0.05),
consistent with its role in decreasing plasma HDL-C, as suggested
by the GLGC and FHS association studies.
The minor allele of the rs344747347 (229 T.G) variant was
highly associated with decreased plasma EL (P,0.004), consistent
with the luciferase reporter assay results. Plasma EL concentra-
tions were measured for individuals in SIRCA genotyped for the
rs2000813 variant (Thr111Ile; n=761). This common nonsynon-
ymous variant does not alter EL lipolytic activity in vitro or in vivo
[20], but was associated with increased HDL-C in GLGC
(P=1.92610
214). Plasma EL concentrations decreased with the
minor allele of the Thr111Ile variant (P,0.0008, Table 6).
It may be that the Thr111Ile variant is in high LD with a regulatory
variant that decreases EL expression, which would explain the
decreased plasma EL of subjects with the Thr111Ile variant, as well as
its association with HDL-C but normal lipolytic activity in GLGC. To
test this possibility, using genotyping data for the common regulatory
variants in SIRCA participants, we estimated their LD with
Haploview software [34]. The rs34474737 (229 T.G) and
rs2000813 (Thr111Ile) variants were in high LD (R
2=0.8)(Figure4).
Discussion
GWAS and candidate gene association techniques clearly
contribute to the identification and validation of candidate genes
Table 2. Identified rare
a LIPG regulatory variants.
Mutation
b High HDL
c Low HDL
d HDL-C (mg/dL)
Variants identified in HHDL Sequencing Cohort
21487 A.G 2 0 124–132
21324 C.T 1 0 104
21234 C.T 1 0 102
21080 G.T 3 0 85–132
2612 C.A 1 0 152
2537 T.C 1 0 100
2410 C.G 1 0 110–114
2403 C.G 2 0 102–108
2274 C.T 2 0 106–108
219 A.G1 09 0
Variants identified in LHDL Sequencing Cohort
21666 G.C 0 2 34–36
21223 A.G0 1 3 3
21052 C.A0 1 3 4
2175 G.A0 1 3 7
44 T.C0 1 3 8
Variants identified in both sequencing cohorts
2324 A.G 3 1 82–102 (HHDL), 44 (LHDL)
2303 A.G 1 2 124 (HHDL), 28–36 (LHDL)
aRare LIPG promoter variants were defined as those with a minor allele
frequency (MAF) of ,0.01 as determined by the number of participants with
each variant relative to the total.
bRelative to transcription start site.
cNumber of individuals with the mutation identified in HHDL Sequencing
Cohort.
dNumber of individuals with the mutation identified in LHDL Sequencing
Cohort.
doi:10.1371/journal.pgen.1002393.t002
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causal variations. Although rare variants hold much promise for
filling this void [35], the association of rare mutations with
continuously distributed phenotypes has been hampered by the
dual presence of functional and nonfunctional mutations.
Moreover, studies have shown a lack of uniformity in incorporat-
ing the functional relevance of rare variants into their analyses.
The direct influence of regulatory variants, for which functional
significance is often ambiguous, also remains largely uncharacter-
ized.
To address the phenotypic contributions of rare and common
regulatory variants, we utilized the continuous trait HDL-C and
candidate gene LIPG, which has significant genome-wide common
and causal coding variations. By uncovering the allelic spectrum of
LIPG regulatory regions through sequencing at the HDL-C
extremes, rare and common regulatory mutations in LIPG were
shown to contribute to observable variation in HDL-C levels. The
findings also demonstrated that the functional impact of identified
variants can help guide statistical analyses that assess their
combined effect on a studied phenotype. To our knowledge, this
study is one of the first applications of a rare variant association
test to regulatory variants for a complex trait, as well as the first of
such analyses to be informed by functional assays.
Association tests for rare variants of complex traits
Numerous methodologies have been described for statistically
comparing the frequency differences of rare coding variants for a
complex trait in cases and controls [22]. Some approaches assume
that much of the heritability of complex traits arises from the
Figure 2. Rare LIPG regulatory variants modulate transcrip-
tional activity in vitro. Relative promoter activity of rare variants
(MAF,0.01) identified from resequencing of high HDL-C individuals (A)
or low HDL-C individuals (B). Plasmid constructs expressing firefly
luciferase under the control of wild-type (WT) or variant LIPG promoters
were individually co-transfected with a Renilla luciferase reporter
construct (pRL-SV40) in HUVECs. Firefly luciferase expression were
measured and normalized to that of Renilla luciferase, and Renilla-
normalized promoter activities for variant constructs were then
compared to those of the WT construct to provide relative LIPG
promoter activities of the variants. Assays were conducted with 6
replicates per experiment and data is given as mean 6 standard
deviation. *P-value,0.05, **P-value,0.01, ***P-value,0.0001, com-
pared with WT.
doi:10.1371/journal.pgen.1002393.g002
Table 4. Identified common
a LIPG regulatory variants.
Mutation
b Genotype
c High HDL
d Low HDL
e
21495 T.C (rs9958947)
f Homozygous 5 (2.6%) 9 (4.7%)
Heterozygous 44 (22.6%) 55 (28.5%)
MAF
h 0.14 0.19
21429 C.A (rs4245232)
f Homozygous 5 (2.6%) 9 (4.7%)
Heterozygous 44 (22.6%) 55 (28.5%)
MAF 0.14 0.19
21309 A.G (rs3829632)
f Homozygous 5 (2.6%) 9 (4.7%)
Heterozygous 44 (22.6%) 55 (28.5%)
MAF 0.14 0.19
21358 T insertion
g Homozygous 1 (0.5%) 0 (0%)
Heterozygous 17 (8.7%) 23 (11.9%)
MAF 0.05 0.06
229 T.G (rs34474737) Homozygous 25 (12.8%) 16 (8.4%)
Heterozygous 96 (49.2%) 103 (55.1%)
MAF 0.37 0.35
aCommon LIPG promoter variants were defined as those with MAF$0.05 as
determined by number of participants with each variant relative to the total.
bRelative to transcription start site.
cHomozygous and heterozygous refer to minor allele.
dNumber identified in HHDL Sequencing Cohort (percentage of total
sequenced in cohort).
eNumber identified in LHDL Sequencing Cohort (percentage of total sequenced
in cohort).
fMinor alleles of 21495, 21429, and 21309 variants were present in a common
haplotype.
gA rs number for this SNP was not present in dbSNP.
hMinor allele frequency, as determined for each cohort.
doi:10.1371/journal.pgen.1002393.t004
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which include CAST and combined multivariate and collapsing
(CMC) method, collapse rare variants within a functional location
(e.g., gene locus) and compare the frequencies of the aggregate
variants between cases and controls [36,37]. Other methods for
evaluating rare, risk-conferring mutations include weighted sum
methods that count both rare and common coding variants. These
tests weight variants based on their frequency in controls [38] or
are informed by computational prediction programs for assessing
functionality [39]. Although these assessment methods demon-
strate high statistical power, they are disadvantaged by their
inclusion of both rare and common variants, as well as functional
information that is largely inapplicable or unavailable for
noncoding variants.
Although the effects of rare missense variants are frequently
deleterious with regard to protein structure and function, the
effects of rare regulatory variants are less readily interpretable
[23,36]. Such variants may cause increased or decreased gene
expression, depending on their location; may act in a tissue-
dependent manner, thereby weakening their association with
complex traits; and may increase, decrease, or not affect
transcription at all. Whereas nonfunctional coding variants can
be predicted easily by synonymous or conservative amino acid
substitutions, similar criteria cannot be applied to regulatory
variants.
We first used CAST to investigate the contribution of rare
regulatory variants to HDL-C without computationally predicting
their effects. The results showed no significant excess of rare
regulatory variants in LIPG in either cohort. However, the strength
of rare variant aggregation methods increases when the functional
validity of the variants is known [22,23,40,41]. Therefore, we
assessed the functional effects of each variant in a cell type that
endogenously expresses LIPG (HUVECs). These putative func-
tional effects were used to reassess the association of functional
variants in the 2 cohorts. Using a modification of CAST, we
separately tested the associations of variants that increase or
decrease LIPG promoter activity. The results showed that variants
segregated with the phenotypic extremes in a manner that was
almost completely consistent with the contribution of the gene to
the phenotype. For example, given that EL inversely affects HDL-
C levels, variants that decrease EL should cause increased HDL-C
and should occur at a higher frequency in high HDL-C
individuals, and vice versa. Including functional information in the
association analysis permitted the near-perfect demonstration of
this distribution.
The only rare regulatory mutation inconsistent with the
expected distribution was the 2303 A.G variant, which increased
Table 5. Association of common variants with HDL in Framingham Heart Study.
Variant 21358 (T insertion) 21309 A.G (rs3829632) rs4939883 rs2156552
Phenotype D S.D.
a P value D S.D.
a P value D S.D.
a P value D S.D.
a P value
HDL 20.09 0.15 20.15 0.0002 20.16 2.28610
27 20.18 1.08610
28
HDL2 20.01 0.84 20.07 0.14 20.10 0.002 20.16 5.14610
27
HDL3 20.17 0.02 20.12 0.01 20.15 2.59610
25 20.13 0.0002
HDL size 20.07 0.36 20.12 0.01 20.11 0.004 20.12 0.002
HDL small particle 20.07 0.38 0.01 0.88 0.06 0.08 0.06 0.13
HDL intermediate
particle
0.04 0.62 0.07 0.16 20.07 0.04 20.07 0.05
HDL large particle 20.1 0.22 20.14 0.004 20.14 0.0002 20.15 9.31610
25
apoA-I 20.11 0.13 20.09 0.05 20.12 0.0003 20.13 0.0001
aDSD represents the fractional change in standard deviation (SD) in standardized residual (mean=0, SD=1 after adjustment for age, age
2, BMI, alcohol intake, smoking
status, menopause, and hormone replacement therapy separately by gender) per copy of minor allele. One SD unit in the Framingham Heart Study was 13.2 mg/dL.
doi:10.1371/journal.pgen.1002393.t005
Figure 3. Common LIPG regulatory variant rs34474737 affects
LIPG promoter activity in vitro. Relative LIPG promoter activity of
common variants rs34474737 (229 T.G) and 21358 T insertion variant
identified from resequencing of individuals with high and low HDL-C
levels, measured as relative firefly luciferase expression of LIPG variant
constructs in HUVECs. Assays were conducted with 6 replicates per
experiment and data is given as mean 6 standard deviation.
**P-value,0.01, compared with WT.
doi:10.1371/journal.pgen.1002393.g003
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and 2 low HDL-C individuals, which is the expected distribution,
given its in vitro functionality. However, the high HDL-C
individual with the 2303 A.G variant also had another rare
LIPG regulatory variant, 21487 A.G, which decreased promoter
activity in vitro. Thus, the actual role of 2303 A.G in contributing
to high HDL-C levels must be considered in the context of the
contribution from the additional rare variant in this individual.
Previously, Hegele et al. presented an elegant approach of
refining association tests by using exclusively presenting coding
variants [42]. In the present study, this approach was modified for
application to noncoding variants. We examined the association of
variant types with the phenotypic extremes after eliminating
variants occurring at both extremes. The results showed that
promoter-activating or -damaging rare LIPG variants occurred
only in individuals with high or low HDL-C, respectively. Thus,
our analysis method effectively enriched for functional variants
with the greatest potential effect at either extreme. A limitation of
this approach is that the exclusivity of any rare variant depends on
the selection criteria and sizes of the cohorts. Nevertheless, even
without this selectivity filter, the expected enrichment of opposing
regulatory variant types occurred at the opposite phenotypic
extremes.
The current literature contains additional rare variant associ-
ation tests that evaluate the contribution of risk and protective rare
variants to complex traits. One is a modified C-alpha score-test
that measures the deviation of variance of each observed mutation
from the expected variance with a binomial distribution. However,
this method may not be valid for evaluating variants occurring
only once in a test cohort, such as were identified in our study [43].
Another method, weighted sum test, calculates 2 one-sided
statistics to quantify the association of variants in either phenotypic
extreme. This test allows the incorporation of functional
information of the identified variants and may be applicable to
measuring the association of rare regulatory variants [44]. Yet
neither of these methods is sufficiently robust to manage the large
number of rare nonfunctional variants likely to be identified in
resequencing studies of regulatory regions. In our study, nearly
half of the rare variants identified in only one extreme failed to
have any transcriptional effect. A recently reported modification of
a previous methodology for studying common variants, the
sequence kernel association test, may prove useful in studying
the association of such rare variants without making any
assumption of the functional direction or degree of effect of any
individual variants [45].
Putative haplotype involving a causal regulatory and a
nonfunctional coding variant of LIPG is associated with
HDL-C levels
Exploration of the LIPG noncoding regions revealed the
contributions of common regulatory variants. For example, the
229 T.G (rs34474737) variant in the 59 UTR was found to
decrease LIPG promoter activity in vitro and to raise plasma EL in
humans. This variant was in LD with the common nonsynon-
Table 6. Association of common LIPG variants with plasma EL concentrations in SIRCA.
LIPG Variant (ref.
allele.minor allele) MAF Effect of minor allele on HDL-C (P value)
e Genotype (N
f) Mean plasma EL
g
Effect of minor allele on
plasma EL (P value)
h
Combined Haplotype
a 0.221
a Q (8.64610
210)
a AA (537)
a 483.56342.1
a q (0.041)
a
AG (202) 538.46368.9
GG (21) 540.26367.9
rs4939883
b (C.T) 0.190
c Q (4.34610
249) CC (542) 481.86353.5 q (1.43610
23)
CT (203) 538.86342.0
TT (10) 772.96452.8
rs2156552
b (T.A) 0.190
c Q (5.53610
245) TT (419) 486.26362.1 q (3.48610
23)
TA (146) 545.16346.5
AA (5) 852.16565.7
rs34474737 (229 T.G) 0.278
d N/A TT (391) 520.16338.3 Q (3.38610
23)
TG (305) 505.76379.3
GG (70) 417.66302.0
rs2000813 (584 C.T;
Thr111Ile)
0.279
c q (1.92610
214) CC (352) 521.26343.5 Q (7.00610
24)
CT (330) 492.76362.9
TT (79) 417.46319.9
aHaplotype block containing variants rs3829632, rs4245232, rs9958947, rs4939875, rs6507929, rs4939583, rs3819166, and rs2000812. Representative minor allele
frequency (MAF; from HapMap, CEU Set, Caucasians from Utah, USA) and effect of minor allele on HDL-C in GLGC GWAS are given for the rs4245232 variant.
Genotyping in SIRCA was completed for the rs3829632 variant and this was used to assess association of the minor allele of this variant with mean plasma EL
concentration. Individual variants, their chromosomal location, and P values for the association of the minor alleles with HDL-C in the Global Lipids Genetics
Consortium (GLGC) GWAS are given in Table S2. R
2 values for LD of individual variants of the haplotype block are given.
bIdentified in the GLGC GWAS [13].
cFrom HapMap (CEU Set, Caucasians from Utah, USA).
dFrom dbSNP (CEU Set, Caucasians from Utah, USA).
eAssociation with HDL-C in the GLGC GWAS.
fNumber of individuals in SIRCA with given genotype whose plasma EL concentrations were measured.
gPre-heparin plasma EL concentrations (ng/mL), shown as mean 6 S.D.
hAssociation of log-transformed mean plasma EL concentration with minor allele for each variant in SIRCA.
doi:10.1371/journal.pgen.1002393.t006
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variant that does not damage EL function (according to the
PolyPhen prediction program) and does not alter EL lipolytic
activity in vitro or in vivo [20]. The association of Thr111lle with
HDL is unclear, with some studies purporting a weak association
with elevated HDL-C and others showing no association
[46,47,48,49,50,51,52]. However, a recent GLGC GWAS metaa-
nalysis of .100,000 individuals revealed significant association of
this variant with increased plasma HDL-C (P=1.92610
214) [13],
suggesting that Thr111Ile may be in LD with a regulatory variant.
Based on the high LD between 229 T.G and Thr111Ile, as
well as the association of plasma EL with minor alleles of the 229
T.G and Thr111Ile variants in SIRCA participants, we propose
that the 229 T.G variant may cause the association of Thr111Ile
with HDL-C by decreasing plasma EL. To our knowledge, this
finding represents the first identification of a putative haplotype
involving a causal regulatory variant and a functionally benign
coding variant. The result also highlights the potential misattri-
bution that can occur when nonsynonymous coding variants are
considered to be highly suggestive of causal mutations, and
regulatory variants are ignored.
Interestingly, there are several reports of common nonsynon-
ymous variants causing the association of noncoding variants in
high LD with a phenotype. Kanda et al. reported that a common
missense variant in high LD with a nearby promoter SNP at
chromosome 10q26 independently explains the association of the
locus with susceptibility to age-related macular degeneration [53].
A common functional missense variant in the B-cell scaffold
protein BANK1 was shown to be in high LD with a common
intronic variant that alters splicing, and both variants were
strongly associated with systemic lupus erythematosus [54]. The
functional heterogeneity of linked coding and noncoding SNPs
highlights the complexity of haplotype structures, as well as the
need to characterize the complete (i.e., coding and noncoding)
variation in candidate loci for complex traits. Indeed, resequencing
studies to identify haplotypes in candidate genes for inflammation,
lipid metabolism, and blood pressure regulation are susceptible to
missing partial or whole haplotype blocks when only coding
variation is considered [55]. Common regulatory variation in
observed haplotypes for several complex traits may have profound
functional significance.
In our analysis of common regulatory variation in LIPG,w e
identified another haplotype with SNPs in the proximal promoter
region. Three variants, 21495 T.C (rs9958947), 21429 C.A
(rs4245232), and 21309 A.G (rs3829632), identified in the
promoter region were in complete LD with each other. A study of
HapMap data indicated that three SNPs upstream of the
sequenced region (rs4839583, rs6507929, and rs4939875) and
SNPs in the second and fifth introns of LIPG (rs2000812 and
rs3819166, respectively) are also in high LD with these three
promoter SNPs [33]. Because the region encompassed by this
haplotype extends far upstream and within the LIPG gene
(approximately 34.1 kb from the most 59 to most 39 of the variant
constituents of the haplotype), it is not possible to assess its full
functional impact with a reporter driven by part of the LIPG
promoter. Characterization of the effects of single variants of this
haplotype on LIPG expression in vitro could lead to erroneous
implications about their functional significance, because their
aggregate (and potentially synergistic) effects on transcription
would be ignored. Therefore, we evaluated the contribution of the
combined haplotype by measuring its effect on HDL-C levels and
plasma EL concentrations from human subjects. Minor alleles of
the haplotype variants were associated with decreased HDL-C in
the FHS and GLGC GWAS studies, and the minor allele of 1
variant was associated with increased plasma EL. Together, these
findings implicate this haplotype in the reduction of human HDL-
C.
Association of minor alleles of the 21309 A.G, rs4939883, and
rs2156552 variants with decreased HDL-C (P=0.0002,
2.28610
27, and 1.08610
28, respectively) in the FHS was
supported by a similar association with decreases in the HDL
subphenotypes HDL2 and HDL3. A recent GWAS of 17
nonconventional, NMR-assessed lipoprotein measures also iden-
tified association of the rs4938993 variant with apoA-I and large
HDL particles under both fasting and nonfasting conditions [56].
Together, these results demonstrate the reproducibility of such
measurements in association studies. Future lipid genetic associ-
ation studies using nonstandard measurements may provide
additional insights beyond aggregate lipoprotein measures.
Finally, we evaluated 2 SNPs, rs2156552 and rs4299883, which
were recently reported in the GLGC GWAS metaanalysis to be
highly associated with HDL-C. Both variants are 40–65 kb
downstream of the LIPG gene and are in high LD with each
Figure 4. Linkage disequilibrium of rs34474737 (229 T.G) and
rs2000813 (Thr111Ile) variants. Genotyping of rs34474737 and
rs2000813 variants was completed in SIRCA participants (761 in total).
LD was estimated and plotted using this genotyping data using
Haploview software. Values in the LD plot are estimated squared
correlation coefficients (R
2).
doi:10.1371/journal.pgen.1002393.g004
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being associated with decreased HDL-C, the minor alleles of these
variants are associated with increased plasma EL in humans. We
did not observe any LD with any of the common variants
identified in our resequencing study. Further analysis of the
regulatory region harboring these SNPs may help elucidate the
mechanism by which these variants contribute to increased human
LIPG expression.
The molecular regulators of LIPG expression are largely
unknown. Investigations of induced EL secretion from human
endothelial cells upon cytokine treatment have suggested that
LIPG is regulated in an NFkB-dependent manner [57]. Subse-
quent studies utilizing electrophoretic mobility shift assays,
chromatin immunoprecipitation (ChIP), and cotransfection exper-
iments of luciferase reporter constructs determined that the LIPG
promoter contains 2 NFkB binding sites, one of which (position
21250 relative to the transcription start site) exhibited strong
NFkB binding in vitro [58]. In addition, ChIP combined with
genome tiling arrays in HepG2 liver cell lines identified LIPG as a
potential target of the SREBP1 transcription factor, a major
regulator of cellular fatty acid synthesis and metabolism [59].
None of the promoter variants identified in this study disrupt the
NFkB or SREBP1 binding sites. Further characterization of
regulatory variants affecting LIPG expression may help elucidate
key regulators of LIPG expression.
Conclusions
In this study, we demonstrate that regulatory variants, both
common and rare, causally contribute to an associated phenotype.
Given the complexities of interpreting the functionality of
noncoding variants, direct experimental evaluation may be
required to assess their impact accurately. By expanding on
previous statistical association methods, this study provides an
example of how such an evaluation may be done. As future whole-
genome sequencing efforts will undoubtedly uncover myriad
causal regulatory mutations for several polygenic traits, the
findings in this study should encourage the development of
methodologies to assess the contribution of rare noncoding
variants.
Materials and Methods
Ethics statement
Written informed consent was obtained from all participants in
the cohorts described. The UPenn Institutional Review Board
(IRB) approved all study protocols.
Research participants for the sequencing cohorts
LIPG regulatory variants were identified in a discovery cohort of
subjects selected from the extremes of the HDL-C phenotypic
distribution in the following cohorts: University of Pennsylvania
(UPenn) High HDL Cholesterol Study (HHDL), UPenn Cathe-
terization cohort (PennCATH), Study of Inherited Risk of
Coronary Atherosclerosis (SIRCA), and Philadelphia Area Met-
abolic Syndrome Network (PAMSyN).
HHDL is a cross-sectional study of genetic factors contributing
to elevated HDL-C levels. Individuals with elevated HDL-C
(.90
th percentile for age and gender) were identified by physician
referrals or through the Hospital of the UPenn clinical laboratory.
PennCATH is composed of consecutive subjects undergoing
coronary angiography at UPenn Health System hospitals and has
been previously described [60]. SIRCA is a cross-sectional study of
factors associated with coronary artery calcification in asymptom-
atic subjects recruited on the basis of a family history of premature
coronary artery disease. Study design and initial findings have
been previously published [61]. PAMSyN is a cross-sectional study
of individuals with varying numbers of metabolic syndrome
criteria, from none to all 5.
High HDL participants and low HDL participants were chosen
from these cohorts. HHDL Sequencing Cohort participants are
subjects with elevated HDL-C ($95th percentile) for age and sex
(females, range 87–174 mg/dL; males, range 85–166 mg/dL).
LHDL Sequencing Cohort participants are subjects with low
HDL-C (#25th percentile), excluding individuals with HDL-C
,20 mg/dL to eliminate participants with likely monogenic
disorders of lipoprotein metabolism, leading to reduced HDL-C
concentration (females, range 22–61 mg/dL; males, range 23–
44 mg/dL). Approximately 92% of participants were Caucasian,
while the remaining 8% were of African descent; 42% of the
participants were males, which was representative of the overall
demographics of the parent studies. In total, 195 high HDL
participants and 193 low HDL participants were chosen for deep
resequencing analysis of the LIPG promoter.
Research participants in Framingham Heart Study
association
The Framingham Heart Study (FHS) Offspring Cohort,
consisting of 5124 participants who were offspring of the original
cohort recruited in 1948 and the spouses of the offspring, was
initiated in 1971. Participants have been examined every 4 to 8
years. The examined genotypes were from a panel of 1778
unrelated individuals who provided blood samples for DNA
extraction during the sixth examination cycle (1995–1998). HDL
measurements were available at up to 7 time points for each
individual. The HDL mean from the available measures for each
individual was used. HDL2, HDL3, HDL size, HDL subfractions,
and apoA-I, measured at exam 4, were determined as described
previously [62,63,64]. The Institutional Review Board at Boston
Medical Center approved the study, and all participants gave
written informed consent.
Sequencing
A 1755-bp region of the promoter region (directly upstream of
the transcription start site) of LIPG was amplified using a
polymerase chain reaction (PCR)-based strategy. Genomic DNA
was isolated from peripheral blood leukocytes using Nucleon
extraction and purification protocols (Amersham). PCR reactions
containing 200 ng of DNA template using Ready-to-Go PCR
Beads (Amersham) were amplified in a final volume of 25 mL. The
PCR program included denaturation at 95uC for 5 min, followed
by 35 cycles (95uC for 1 min, 61.5uC for 30 s, and 72uC for
1 min), and extension at 72uC for 2 min. PCR products were
purified with ExoSAP-IT (USB, Cleveland, OH). Purified PCR
products were analyzed via Sanger sequencing on an ABI
sequencer with Big Dye (Applied Biosystems) terminator chemis-
try. Sequences were aligned and chromatograms viewed with
Sequencher Version 4.8 (Gene Codes) software. Allelic variations
were verified by inspecting chromatograms. Putative variants
identified in the HHDL and LHDL Sequencing Cohorts were
searched for in the 1000 Genomes Project database. Rare variants
were those with ,1% MAF in our sequencing cohorts, and
common variants were those with $5% MAF in our sequencing
cohorts.
Genotyping
The 21309 A.G (rs3829632) and 21358 (T insertion) variants
were genotyped in participants of the FHS for association analysis
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genotyping assays (Applied Biosystems). For association of
common variants with plasma EL concentration in SIRCA
participants, genotyping was completed by using either Taqman
custom genotyping assays (for 21309 A.G [rs3829632], 229
T.G [rs34474737], and rs4299883) or the ITMAT-Broad-CARe
(IBC) cardiovascular gene genotyping array [65]. DNA was
diluted to 50 ng/mL, and genotyping was performed at the Center
for Applied Genomics (Children’s Hospital of Pennsylvania)
following manufacturer specifications for amplification and
hybridization to the IBC array (HumanCVD beadchip, Illumina),
as previously described [66].
Plasmid constructs and site-directed mutagenesis
A 2007-bp fragment consisting of the human LIPG promoter
(1755-bp portion flanking the transcription start site) and the 59
untranslated region (252-bp) was PCR-amplified from a human
LIPG plasmid clone with PCR primers that introduced Kpn I and
Xho I restriction sites at the 59 and 39 ends of the fragment,
respectively. This amplified region was cloned into the pGL3-basic
vector (Promega) with the Kpn I and Xho I restriction sites to
generate a construct with wild-type LIPG promoter driving firefly
luciferase expression and was confirmed by PCR.
Mutagenesis of the wild-type LIPG promoter (firefly luciferase)
construct to generate mutant constructs for each of the identified
regulatory variants was achieved by using QuikChange Site-
Directed Mutagenesis Kit (Stratagene) according to the manufac-
turer’s directions with primer sequences available in Table S3.
Plasmids were sequenced after site-directed mutagenesis to
confirm the changes and to rule out additional nonspecific
changes.
Cell culture and dual-reporter luciferase assays
Clonetics human umbilical vein endothelial cells (HUVEC,
Lonza) were cultured in Clonetics Endothelial Growth Medium
(EGM-2, Lonza) at 37uC, 5% (v/v) CO2. In preparation for
luciferase assays, HUVECs were passaged 3 times and plated
(10,000 cells/well) overnight in 96-well tissue culture grade
black-and-white microplates (Perkin-Elmer) in EGM-2. Cells
were transfected by using 2 mgD N A / w e l l( LIPG promoter
construct and pRL-SV40 in a 50:1 ratio) and Fugene HD
transfection reagent (Roche) in a 1:3 ratio of DNA to Fugene
HD following the manufacturer’s instructions. Cells were
harvested at 36 h after transfection. Luciferase assays were
performed with the Dual Luciferase Assay Kit (Promega) and a
dual-injection microplate luminometer (Orion Microplate Lu-
minometer, Berthold Detection Systems). Each well was
normalized by Renilla luciferase luminescence values. Normal-
ized values were compared to wild-type LIPG promoter
constructs transfected on the same plate. Each construct was
transfected with 6 replicate wells for each experiment. Each
construct was evaluated at least three times.
Enzyme-linked immunosorbent assays
The preheparin mass of EL was measured from the plasma of
SIRCA study participants genotyped for some of the identified
common variants and 2 GWAS-identified noncoding variants.
Detailed methods of the EL sandwich ELISA have been reported
previously [67,68]. Briefly, rabbit anti-human EL antibody was
used to capture EL from diluted plasma samples, followed by
incubation with biotin-conjugated rabbit anti-human EL antibody
and streptavidin-horseradish peroxidase conjugate with O-phe-
nylenediamine for detection.
Statistical analyses
Analysis and comparison of promoter activity between wild-type
and variant LIPG promoter constructs from the luciferase assays
were conducted by using unpaired Student’s t-tests (P-values,0.05
were considered to be statistically significant). Numbers of
individuals with a rare variant identified in each sequencing
cohort were initially compared using 2-tailed Fisher’s exact tests.
Variants that did not alter promoter activity in vitro were
discounted, and individuals harboring these variants were included
in their respective sequencing cohort as individuals without a
functionally altering variant. Numbers of individuals with variants
decreasing promoter activity and with variants decreasing
promoter activity in each sequencing cohort were then compared
separately using 1-tailed Fisher’s exact tests.
The FHS association analysis was completed by performing
multiple linear regressions of the residuals of lipid phenotypes,
separately by gender, after adjustment for means of age, age
2,
BMI, alcohol intake, and smoking status. In this analysis, for
women, the proportion of exams that a woman was menopausal
and on hormone replacement therapy was included as a covariate.
For association of variant genotypes with effect on plasma EL in
SIRCA, plasma EL concentrations were log-transformed to
normalize the distribution and analyzed with linear regression.
Linkage disequilibrium (LD) calculations and presentation were
performed with Haploview software [34].
Supporting Information
Figure S1 Expression of LIPG promoter construct in HUVECs.
Relative LIPG promoter activity of WT LIPG promoter construct
(1755-bp of LIPG promoter and 59 UTR driving expression of
firefly luciferase) and pGL3-basic construct (no functional
promoter) in HUVECs. Firefly luciferase activity of WT construct
was normalized to that of cotransfected Renilla luciferase, and
Renilla-normalized promoter activity was normalized to that of
pGL3-basic construct to determine functionality of WT promoter
construct in HUVECs for subsequent analysis of variant
constructs. Assays were conducted with 6 replicates per experi-
ment and data is given as mean 6 standard deviation.
***P,0.0001 relative to pGL3-basic.
(TIF)
Figure S2 Functional analysis of additional rare LIPG regulatory
variants identified. Relative promoter activity of rare variants
(MAF,0.01) identified from resequencing of individuals with high
HDL-C levels (A) or low HDL-C levels (B) which did not alter
LIPG promoter activity in vitro, and of rare variants present in
both high HDL-C and low HDL-C cohorts (C). Plasmid constructs
expressing firefly luciferase under the control of wild-type (WT) or
variant LIPG promoters were individually co-transfected with a
Renilla luciferase reporter construct (pRL-SV40) in HUVECs.
Firefly luciferase expression were measured and normalized to that
of Renilla luciferase, and Renilla-normalized promoter activities
for variant constructs were then normalized to those of the WT
construct to provide relative LIPG promoter activities of the
variants. Assays were conducted with 6 replicates per experiment
and data is given as mean 6 standard deviation.
(TIF)
Figure S3 Linkage disequilibrium in and surrounding the LIPG
promoter. LD was estimated for 3 common LIPG promoter
variants (rs3829632, rs4245232 and rs9958947) and additional
common variants upstream and in intronic regions of LIPG from
HapMap CEU population dataset using Haploview software.
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coefficients (R
2).
(TIF)
Table S1 Characteristics of participants in sequencing cohorts
with rare LIPG regulatory variants.
(DOCX)
Table S2 Association of LIPG combined haplotype variants with
HDL-C in GLGC GWAS.
(DOCX)
Table S3 Primers used for site-directed mutagenesis to generate
LIPG promoter variant constructs.
(DOCX)
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